Immunotherapy and carbon ion radiation for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new treatment that combines immunotherapy (drugs that help your immune system fight cancer) with carbon ion radiation (a precise type of radiation) for people with locally advanced cervical cancer that hasn't spread to other organs. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with cervical cancer (squamous cell, adenocarcinoma, or adenosquamous type).
- Your cancer is stage IIB, III, or IVA (it has spread locally but not to distant organs).
- You have not had any previous surgery, radiation, or chemotherapy for cervical cancer.
- You are able to have carbon ion radiation and are willing to receive it at Zhejiang Cancer Hospital and pay for it.
- You have not had prior immunotherapy (like anti-PD-1 or anti-PD-L1 drugs).
- You do not have active infections, serious health problems, or autoimmune diseases requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an “adaptive” type of radiation planning using proton therapy and MRI-guided brachytherapy can improve treatment for people with cervical cancer. It aims to deliver curative treatment more precisely while still combining it with chemotherapy (cisplatin) when appropriate.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests a new approach for advanced cervical cancer: giving immunotherapy (a drug that helps your immune system fight cancer) before and during standard chemoradiation. The goal is to see if adding immunotherapy can shrink the tumor more and improve outcomes.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial is testing a combination of standard chemotherapy and radiation delivered to the pelvis, followed by an internal radiation treatment guided by CT scans. The goal is to improve treatment for locally advanced cervical cancer while potentially reducing side effects.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.